Refoxy Pharmaceuticals develops small molecule activators targeting the FOXO3 transcription factor to treat age-related diseases, particularly Idiopathic Pulmonary Fibrosis. By enhancing FOXO3 activity, the company aims to improve cellular homeostasis and combat fibrotic and cardiovascular disorders, addressing the need for effective therapies in these complex conditions.
Funding
$9.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BIFounders
Product
Problem
Current treatments for age-related diseases often target single proteins or pathways, yielding limited success due to the complex and multifactorial nature of these disorders. There is a need for therapies that can address multiple biological processes simultaneously to achieve greater therapeutic effects and improve overall healthspan.
Solution
Refoxy Pharmaceuticals is developing small molecule activators of the FOXO3 transcription factor to treat age-related diseases, particularly fibrotic and cardiovascular disorders. Their discovery platform, F.act finder, identifies and optimizes novel FOXO3 activators that are functionally relevant across diverse disease models. By targeting FOXO3, a master regulator of cellular homeostasis and stress response, Refoxy aims to improve cellular function and combat age-related pathologies. Their lead asset exhibits robust anti-fibrotic properties and is being explored for its therapeutic impact in Idiopathic Pulmonary Fibrosis (IPF).
Target Audience
The primary target audience includes individuals affected by age-related diseases such as Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic and cardiovascular disorders, as well as pharmaceutical companies seeking novel therapeutics in these areas.
Features
- Proprietary F.act finder platform for identifying and optimizing FOXO3 small molecule activators
- Phenotypic screening and unbiased assessments of FOXO3 specificity
- Built-in safety and counter screening measurements to minimize off-target effects
- Lead asset with demonstrated anti-fibrotic properties
- Pipeline of molecules being profiled as potential therapeutics in diverse disorders